TitleProliferation of cardiomyocytes derived from human embryonic stem cells is mediated via the IGF/PI 3-kinase/Akt signaling pathway.
Publication TypeJournal Article
Year of Publication2005
AuthorsMcDevitt, TC, Laflamme, MA, Murry, CE
JournalJournal of Molecular and Cellular Cardiology
Date PublishedDecember 2005
ISSN0022-2828
KeywordsAnimals, Cell Proliferation, Cells, Cultured, Dose-Response Relationship, Drug, Embryo, Mammalian, Heart Diseases, Humans, Insulin-Like Growth Factor I, Insulin-Like Growth Factor II, Mice, Myocytes, Cardiac, Phosphatidylinositol 3-Kinases, Proto-Oncogene Proteins c-akt, Signal Transduction, Stem Cells
Abstract

Cardiomyocytes from common experimental animals rapidly exit the cell cycle upon isolation, impeding studies of basic cell biology and applications such as myocardial repair. Here we examined proliferation of cardiomyocytes derived from human and mouse embryonic stem (ES) cells. While mouse ES cell-derived cardiomyocytes showed little proliferation, human cardiomyocytes were highly proliferative under serum-free conditions (15-25% BrdU+/sarcomeric actin+). The cells exhibited only a small serum dose-response, and proliferation gradually slowed with increasing differentiation of the cells. Neither cell density nor different matrix attachment factors affected cardiomyocyte proliferation. Blockade of phosphatidylinositol 3-kinase (PI 3-kinase) and Akt significantly reduced cardiomyocyte proliferation, whereas MEK inhibition had no effect. Antibody blocking of the insulin-like growth factor-1 (IGF-1) receptor significantly inhibited cardiomyocyte proliferation, while addition of IGF-1 or IGF-2 stimulated cardiomyocyte proliferation in a dose-dependent manner. Thus, cardiomyocytes derived from human ES cells proliferate extensively in vitro, and their proliferation appears to be mediated primarily via the PI 3-kinase/Akt signaling pathway, using the IGF-1 receptor as one upstream activator. This system should permit identification of regulatory pathways for human cardiomyocyte proliferation and may facilitate expansion of cardiomyocytes from human ES cells for therapeutic purposes.

DOI10.1016/j.yjmcc.2005.09.007
Alternate JournalJ. Mol. Cell. Cardiol.
PubMed ID16242146
PubMed Central IDPMC3505759
Grant ListR24 HL064387-05 / HL / NHLBI NIH HHS / United States
R01 HL061553-07 / HL / NHLBI NIH HHS / United States
R01 HL061553 / HL / NHLBI NIH HHS / United States
P20 GM069983-03 / GM / NIGMS NIH HHS / United States
P20 GM069983 / GM / NIGMS NIH HHS / United States
P01 HL003174-50 / HL / NHLBI NIH HHS / United States
P01 HL003174 / HL / NHLBI NIH HHS / United States
HL64387 / HL / NHLBI NIH HHS / United States
HL61553 / HL / NHLBI NIH HHS / United States
HL3174 / HL / NHLBI NIH HHS / United States
HL07403-25 / HL / NHLBI NIH HHS / United States
GM69983 / GM / NIGMS NIH HHS / United States
T32 HL007403 / HL / NHLBI NIH HHS / United States
T32 HL007403-25 / HL / NHLBI NIH HHS / United States